


# Alzheimer's Disease ACE Simulator

**Comprehensive, extensively documented, multi-application model** designed to support commercial strategy development, inform clinical trial designs, and meet HTA requirements for formal submissions in Alzheimer's disease (AD).

- Assesses interventions from the earliest (i.e., mild cognitive impairment or prodromal AD) through the most severe stages of disease, as well as the transition from normal cognitive function.
- Addresses the complex interactions between multiple components of AD pathology (e.g., biomarkers, cognition, behavior, function) and their roles in disease progression.
- Fully considers interrelated clinical, epidemiologic, and economic outcomes, providing a platform that allows for rapid incorporation of intervention-specific data.
- Programmed in MS Excel®, it does not require any additional software, is very transparent, and may be readily modified to address the specific features of the therapy or diagnostic that is being studied.



## Our Team & EXPERIENCE

— 15+ —

Years of experience supporting modeling needs of numerous cholinesterase inhibitors and other Alzheimer's disease products

— 50+ —

Peer-reviewed publications and presentations on Alzheimer's disease and mild cognitive impairment (MCI)

— 400+ —

Health and economic models developed across all therapeutic areas for countries around the globe

— 70+ —

Research projects in Alzheimer's disease, with 20+ in economic modeling since 2010

## Why EVIDERA?

— Expertise —

Developed the AHEAD<sup>1</sup> and AHEAD II models, which are among the most cited dementia models, and have been instrumental in securing positive reimbursement decisions from numerous agencies, including NICE

— Innovative —

Introduced discrete event simulation (DES) to the field in 2000; still at the forefront of modeling methods, e.g., discretely integrated condition event (DICE) simulation, MCDA, clinical trial simulation

— Leaders —

Numerous industry leadership roles, e.g., ISPOR-SMDM Task Force, ISPOR MCDA Task Force, and ISPOR Oncology Special Interest Group

— Influence —

Evidera's modeling and simulation team has supported submissions to NICE, CADTH, IQWiG, FDA, PBAC, and others

"Your commitment to conducting quality research, knowledge of state-of-the-art methodologies, attention to detail and flexibility in the research process all combine to produce important and credible findings. Add collegiality and good cheer and the combination is quite impressive."

Director, Health Economics and Outcomes Research, Top 10 Pharmaceutical Company

<sup>1</sup> AHEAD = Assessment of Health Economics in Alzheimer's Disease